All In MedTech

Device Trial Radar · NCT07689812

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Continuous Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced/Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 920 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

920

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Aug 2034

Study completion May 2036

Sponsor

Lead sponsor
Natera, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 8, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI therapy in patients with histologically confirmed advanced/metastatic non-small cell lung cancer (NSCLC), melanoma, microsatellite instability-high (MSI-High)/Deficient Mismatch Repair (dMMR) colorectal cancer (CRC), renal cell carcinoma (RCC) and other solid tumors. This study will be conducted in approximately to 100 sites.

Conditions

  • NSCLC (Advanced Non-small Cell Lung Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • NSCLC (Non-small Cell Lung Carcinoma)
  • NSCLC
  • Melanoma (Skin Cancer)
  • Melanoma (Skin) Stage IV
  • CRC
  • MSI High Colorectal Cancer
  • DMMR Colorectal Cancer
  • RCC, Renal Cell Cancer
  • RCC
  • Solid Tumors
  • Metastatic Solid Tumors
  • Advanced Solid Tumors
  • Advanced Solid Tumors Cancer

Interventions

  • Signatera Genome ultra-sensitive ctDNA blood testDevice

    The test is used to monitor for disease recurrence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate that ctDNA-guided intermittent ICI therapy results in at least 50% of patients who do not reinitiate systemic therapy prior to 6 months from randomization.Time frame: 6 months from randomization
  2. To demonstrate that ctDNA-guided intermittent ICI therapy is non-inferior to SoC continuous ICI therapy as measured by 36 month OS in advanced/metastatic solid tumor patients.Time frame: 3 years from randomization to death from any cause

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.